Open Access
ARTICLE
Three Combined Treatments, a Novel HDAC Inhibitor OBP-801/YM753, 5-Fluorouracil, and Paclitaxel, Induce G2 Phase Arrest Through the p38 Pathway in Human Ovarian Cancer Cells
Makoto Akiyama*†, Yoshihiro Sowa*, Tomoyuki Taniguchi*, Motoki Watanabe*, Shingo Yogosawa‡, Jo Kitawaki†,Toshiyuki Sakai*
* Department of Molecular-Targeting Cancer Prevention, Kyoto Prefectural University of Medicine,
Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, Japan
† Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji,
Kamigyo-ku, Kyoto, Japan
‡ Department of Public Health and Environmental Medicine, The Jikei University School of Medicine,
Nishi-Shimbashi, Minato-ku, Tokyo, Japan
Oncology Research 2017, 25(8), 1245-1252. https://doi.org/10.3727/096504017X14850164661097
Abstract
Ovarian cancer is the most lethal disease among gynecological malignancies. More effective therapy is
required to counter high recurrence rates and chemotherapy resistance. We investigated the efficacy and
molecular mechanisms of three combined treatments (TCTs)—a novel histone deacetylase (HDAC) inhibitor OBP-801/YM753, 5-fluorouracil (5-FU), and paclitaxel (PTX)—in human ovarian cancer SKOV-3 and
OVCAR-3 cells. The inhibition of cell growth was stronger with TCTs than with each single agent and with
two combined treatments. The TCTs significantly induce G
2 phase arrest in both cell lines. We then analyzed
the molecular mechanisms and found that the TCTs increased the phosphorylation of p38 (Thr180/Tyr182),
decreased the expression of CDC25C, and increased the phosphorylation of CDC2 (Tyr15), an inactive form
of CDC2. To examine the responsibilities of the p38 pathway for G
2 phase arrest induced by the TCTs, we
employed the p38 inhibitor SB203580. SB203580 inhibited G
2 phase arrest, suppression of CDC25C, and
phosphorylation of CDC2 (Tyr15) induced by the TCTs. These results suggest that the TCTs can induce
G
2 phase arrest through activation of the p38 signaling pathway. We therefore believe that this combination
is promising as a novel therapeutic strategy against ovarian cancer.
Keywords
Cite This Article
APA Style
Akiyama, M., Sowa, Y., Taniguchi, T., Watanabe, M., Yogosawa, S. et al. (2017). Three combined treatments, a novel HDAC inhibitor OBP-801/YM753, 5-fluorouracil, and paclitaxel, induce g2 phase arrest through the p38 pathway in human ovarian cancer cells. Oncology Research, 25(8), 1245-1252. https://doi.org/10.3727/096504017X14850164661097
Vancouver Style
Akiyama M, Sowa Y, Taniguchi T, Watanabe M, Yogosawa S, Kitawaki J, et al. Three combined treatments, a novel HDAC inhibitor OBP-801/YM753, 5-fluorouracil, and paclitaxel, induce g2 phase arrest through the p38 pathway in human ovarian cancer cells. Oncol Res. 2017;25(8):1245-1252 https://doi.org/10.3727/096504017X14850164661097
IEEE Style
M. Akiyama et al., "Three Combined Treatments, a Novel HDAC Inhibitor OBP-801/YM753, 5-Fluorouracil, and Paclitaxel, Induce G2 Phase Arrest Through the p38 Pathway in Human Ovarian Cancer Cells," Oncol. Res., vol. 25, no. 8, pp. 1245-1252. 2017. https://doi.org/10.3727/096504017X14850164661097